CTO1681

CytoAgents presented new preclinical data on its investigational compound CTO1681 at the 2026 EADV Congress, the European Academy of Dermatology and Venereology's annual meeting. The company says the findings support the drug candidate's development potential in dermatology. Details of the data and the indication being targeted have not been broadly reported, and the announcement is drawing attention from investors and dermatology specialists following the congress presentation.